Drug-eluting stents (DES) are widely used as first choice devices in percutaneous coronary interventions (PCI). However, certain concerns are associated with the use of DES, i.e. neo-atherosclerosis, late stent thrombosis and hypersensitivity reactions to the DES polymer. Bioresorbable scaffolds (BRS) such as the Absorb Bioresorbable Vascular Scaffold (BVS) are the next development within the field of PCI, introducing the concept of supporting the natural healing process following initial intervention without leaving any foreign body materials resulting in late adverse events. The first-generation devices have shown encouraging results in multiple studies of selected patients with non-complex lesions up to the point of full bioresorption. It supported the introduction in regular patient care. During its introduction in daily clinical practice outside the previous selected patient groups, a careful approach should be followed in which outcome is continuously monitored. The aim of this thesis was to investigate the safety and efficacy of the Absorb BVS in more complex lesions and higher-risk patients, when treated in a diverse clinical practice.

Additional Metadata
Keywords Bioresorbable vascular scaffold, percutaneous coronary intervention
Promotor R.J.M. van Geuns (Robert Jan) , Y. Onuma (Yoshinobu)
Publisher Erasmus University Rotterdam
ISBN 978-94-6361-234-0
Persistent URL hdl.handle.net/1765/116450
Felix, C.M. (2019, June 7). Absorb Bioresorbable Vascular Scaffold (BVS) for the treatment of coronary artery disease in clinical practice. Erasmus University Rotterdam. Retrieved from http://hdl.handle.net/1765/116450

Additional Files
Cordula-Felix-stellingenv2.pdf , 520kb
116450_General_Introduction.pdf Final Version , 129kb
116450_Chapter_1-Current_status_of_clinically_available_b.pdf Final Version , 1mb
116450_Chapter_2-Appropriate_use_of_bioresorbable_vascula.pdf Final Version , 160kb
116450_Chapter_3-Expanded_clinical_use_of_everolimus_elut.pdf Final Version , 3mb
116450_Chapter_4-Conformability_in_everolimus-eluting_bio.pdf Final Version , 4mb
116450_Chapter_5-Mid-_to_long-term_clinical_outcomes_of_p.pdf Final Version , 1mb
116450_Chapter_6-Are_BVS_suitable_for_ACS_patients.pdf Final Version , 779kb
116450_Chapter_7-Initial_experience_with_everolimus-eluti.pdf Final Version , 353kb
116450_Chapter_8-Everolimus-eluting_bioresorbable_vascula.pdf Final Version , 4mb
116450_Chapter_9-Impact_of_calcium_on_procedural_and_clin.pdf Final Version , 1mb
116450_Chapter_10-Mid-term_CCTA_results_for_Absorb_biores.pdf Final Version , 4mb
116450_Chapter_11-Angiographic_and_optical_coherence_tomo.pdf Final Version , 10mb
116450_Chapter_12-Treatment_of_bioresorbable_scaffold_fai.pdf Final Version , 7mb
116450_Chapter_13-Very_late_scaffold_thrombosis_in_Absorb.pdf Final Version , 120kb
116450_Chapter_15-Mid-term_outcomes_of_the_BVS_versus_sec.pdf Final Version , 3mb
116450_Chapter_14-Potentially_increased_incidence_of_scaf.pdf Final Version , 682kb
116450_Chapter_16-Summary.pdf Final Version , 113kb
116450_Chapter_17-General_Discussion.pdf Final Version , 144kb
116450_Nederlandse_samenvatting.pdf Final Version , 118kb